Pseudo-Primary Infection Syndrome following Discontinuation of Antiretroviral Therapy

BackgroundShort-term antiretroviral therapy (START) to prevent mother-to-child transmission (MTCT) is currently recommended for all HIV-1-infected pregnant women. The objective of this study was to assess the effect on CD4 cell counts and viral load dynamics the withdrawal of START after birth could generate. MethodsThis was a 5-year cohort study involving HIV-1-infected pregnant women who presented with CD4 counts 4300 cells/mL and had received START to prevent MTCT. ResultsSeventy-five pregnancies were assessed. In 24 cases, there was a history of antiretroviral therapy prior to prophylaxis. The median baseline CD4 count was 573 cells/mL. In 75% of cases, prophylaxis was started after 26.6 weeks of gestation. The median CD4 cell count increase over baseline during prophylaxis was 24.5%. In only five cases did HIV-1 viral load remain detectable during prophylaxis. After START, CD4 cell counts did not drop significantly, and the HIV-1 viral load plateau was near the baseline level. The estimated mean time for CD4 count to fall below 300 cells/mL was 3.5 years and was directly associated with high baseline CD4 cell count, as well as with CD4 increase after prophylaxis, whereas it was negatively correlated with previous use of antiretroviral (ARV) drugs and persistence of detectable HIV-1 viral load during prophylaxis. ConclusionsA potent, well-tolerated prophylactic ARV regimen can improve CD4 cell counts during and after START. In women receiving such prophylaxis, there is a remarkable time interval for CD4 cell counts to drop to levels that indicate treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pseudo-Primary Infection Syndrome following Discontinuation of Antiretroviral Therapy

Abstract: We report the case of a retroviral rebound syndrome associated with parotid gland enlargement in a chronically HIV-infected man.

Cited by 3 publications

References 23 publications

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy

Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman

Short‐term antiretroviral therapy to prevent mother‐to‐child transmission is safe and results in a sustained increase in CD4 T‐cell counts in HIV‐1‐infected mothers^*

Contact Info

Product

Resources

About

Pseudo-Primary Infection Syndrome following Discontinuation of Antiretroviral Therapy

Abstract: We report the case of a retroviral rebound syndrome associated with parotid gland enlargement in a chronically HIV-infected man.

Cited by 3 publications

References 23 publications

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy

Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy

Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman

Short‐term antiretroviral therapy to prevent mother‐to‐child transmission is safe and results in a sustained increase in CD4 T‐cell counts in HIV‐1‐infected mothers*

Contact Info

Product

Resources

About

Short‐term antiretroviral therapy to prevent mother‐to‐child transmission is safe and results in a sustained increase in CD4 T‐cell counts in HIV‐1‐infected mothers^*